標(biāo)題: Titlebook: Biologics in General Medicine; Wolf-Henning Boehncke,Heinfried H. Radeke Book 2007 Springer-Verlag Berlin Heidelberg 2007 Arthritis.Monito [打印本頁(yè)] 作者: CROSS 時(shí)間: 2025-3-21 19:50
書目名稱Biologics in General Medicine影響因子(影響力)
書目名稱Biologics in General Medicine影響因子(影響力)學(xué)科排名
書目名稱Biologics in General Medicine網(wǎng)絡(luò)公開度
書目名稱Biologics in General Medicine網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Biologics in General Medicine被引頻次
書目名稱Biologics in General Medicine被引頻次學(xué)科排名
書目名稱Biologics in General Medicine年度引用
書目名稱Biologics in General Medicine年度引用學(xué)科排名
書目名稱Biologics in General Medicine讀者反饋
書目名稱Biologics in General Medicine讀者反饋學(xué)科排名
作者: STYX 時(shí)間: 2025-3-22 00:08
Infliximab: From the Idea to the Productle and membrane- bound TNF-α . Infliximab does not bind to TNF-β (lymphotoxin α ), a related cytokine that utilizes the same receptors as TNF-α. Thus infliximab was developed as a therapeutic agent for various inflammatory chronic diseases that are believed to be driven by the pro-inflammatory cytok作者: Factorable 時(shí)間: 2025-3-22 04:08 作者: Ischemia 時(shí)間: 2025-3-22 05:16 作者: Anemia 時(shí)間: 2025-3-22 10:45 作者: incite 時(shí)間: 2025-3-22 16:14 作者: macular-edema 時(shí)間: 2025-3-22 21:05
The Production of Biopharmaceuticals chemical synthesis, biologics are made by biosynthesis in living cells. Biologics are generally much larger than traditional synthetic medicinal products and range from highly complex inactivated vaccines and plasma-derived factors to highly purified, well characterised recombinant therapeutic prot作者: 埋葬 時(shí)間: 2025-3-22 22:48
Treating Autoimmune Bullous Skin Disorders with Biologicsng distinct adhesionmolecules of the epidermis and dermoepidermal basement membrane zone leading to a loss of adhesive function of the target antigen(s) (Fig. 8.1). The appearance of blisters and erosions of the skin and/or mucous membranes is the leading clinical sign of autoimmune bullous skin dis作者: prediabetes 時(shí)間: 2025-3-23 02:44
Biologics in Psoriasisune mediated inflammatory changes seen in psoriasis have been elucidated, leading to the development of biologics that specifically act on immunological mechanisms, which are thought to be pathogenic in psoriatic lesions. By acting on specific immunological actions in the large cascade that results 作者: projectile 時(shí)間: 2025-3-23 09:09
Biologic Agents in Psoriatic Arthritisof the population, although estimates of its prevalence vary widely, and is generally considered an autoimmune disease with unknown antigenic determinants. There currently is no predictive marker indicating which psoriasis patients will develop arthritis (Mease 2004). PsA often is classified as a su作者: BUMP 時(shí)間: 2025-3-23 11:33 作者: 肥料 時(shí)間: 2025-3-23 14:30
Biologics in Crohn’s Disease and Ulcerative Colitis: Focus on Tumor Necrosis Factor Antagonistsnagement options for these diseases. The discovery of immunologic and inflammatory mediators, in particular, has paved the way for clinical research with biologic agents in this area. Although conventional treatments remain viable options for some patients, those who are intolerant to these agents a作者: Estrogen 時(shí)間: 2025-3-23 18:06
Multiple Sclerosis: New Immunobiologicsworldwide by this disease, and the relapsing-remitting form of MS exhibits a gender disequilibrium of 3:1 for female affliction. There are several lines of evidence that multiple sclerosis is an autoimmune disease, which may be modified by genetic factors (see review in .). Following the initial for作者: 合唱團(tuán) 時(shí)間: 2025-3-24 01:17
Biologics in Cutaneous Lymphomatracutaneous disease at the time of diagnosis. They can be distinguished into cutaneous T-cell lymphomas (CTCL), cutaneous B-cell lymphomas (CBCL) and the rare precursor dendritic cell neoplasms. The PCL are now classified in the new WHO-EORTC classification (.; Table 14.1).作者: Explicate 時(shí)間: 2025-3-24 04:16 作者: Forage飼料 時(shí)間: 2025-3-24 08:47 作者: 溫和女孩 時(shí)間: 2025-3-24 10:43
Summary and Critical Reflection of efficacy and/or safety problems like infusion reactions. Therefore, chimaeric antibodies such as infliximab (Remicade) were developed, reducing immunogenicity by replacement of the murine Fc part by the human counterpart.作者: 字形刻痕 時(shí)間: 2025-3-24 15:39 作者: Terminal 時(shí)間: 2025-3-24 20:37 作者: 隱士 時(shí)間: 2025-3-25 01:20 作者: 空氣傳播 時(shí)間: 2025-3-25 05:21
Infliximab: From the Idea to the Productle and membrane- bound TNF-α . Infliximab does not bind to TNF-β (lymphotoxin α ), a related cytokine that utilizes the same receptors as TNF-α. Thus infliximab was developed as a therapeutic agent for various inflammatory chronic diseases that are believed to be driven by the pro-inflammatory cytokine TNF-α.作者: ectropion 時(shí)間: 2025-3-25 08:55 作者: BOLT 時(shí)間: 2025-3-25 14:46
Biologics in Cutaneous Lymphomatracutaneous disease at the time of diagnosis. They can be distinguished into cutaneous T-cell lymphomas (CTCL), cutaneous B-cell lymphomas (CBCL) and the rare precursor dendritic cell neoplasms. The PCL are now classified in the new WHO-EORTC classification (.; Table 14.1).作者: –LOUS 時(shí)間: 2025-3-25 15:51 作者: 遺留之物 時(shí)間: 2025-3-25 23:27 作者: 多山 時(shí)間: 2025-3-26 01:01 作者: alleviate 時(shí)間: 2025-3-26 05:30
Claire R. McInerney,Michael E. D. Koenigtem. Examples include antibodies directed against very specific molecular components of the immune response, for example, pro-inflammatory cytokines, or naturally occurring cytokine inhibitors such as IL-1 receptor antagonist (IL-1ra).作者: 用樹皮 時(shí)間: 2025-3-26 11:09 作者: 小說(shuō) 時(shí)間: 2025-3-26 14:23
https://doi.org/10.1007/978-3-319-03698-4n overreactive immune system. Carrier substances that falsely inform the body about an ongoing infection are produced in large quantities. The immune system answers by starting a strong immune response. The body’s own tissues are attacked and continuously destroyed. Specific models of reaction have 作者: 玩忽職守 時(shí)間: 2025-3-26 18:52
Springer Texts in Business and Economicsle and membrane- bound TNF-α . Infliximab does not bind to TNF-β (lymphotoxin α ), a related cytokine that utilizes the same receptors as TNF-α. Thus infliximab was developed as a therapeutic agent for various inflammatory chronic diseases that are believed to be driven by the pro-inflammatory cytok作者: intoxicate 時(shí)間: 2025-3-26 22:13 作者: 陰謀小團(tuán)體 時(shí)間: 2025-3-27 02:39 作者: 駭人 時(shí)間: 2025-3-27 09:04 作者: 玉米棒子 時(shí)間: 2025-3-27 13:06 作者: 中子 時(shí)間: 2025-3-27 16:48 作者: forecast 時(shí)間: 2025-3-27 21:21 作者: 攀登 時(shí)間: 2025-3-27 22:29 作者: Confirm 時(shí)間: 2025-3-28 06:09
https://doi.org/10.1007/978-3-540-24778-4of the population, although estimates of its prevalence vary widely, and is generally considered an autoimmune disease with unknown antigenic determinants. There currently is no predictive marker indicating which psoriasis patients will develop arthritis (Mease 2004). PsA often is classified as a su作者: 郊外 時(shí)間: 2025-3-28 07:56
Claire R. McInerney,Michael E. D. Koenigtem. Examples include antibodies directed against very specific molecular components of the immune response, for example, pro-inflammatory cytokines, or naturally occurring cytokine inhibitors such as IL-1 receptor antagonist (IL-1ra).作者: 壁畫 時(shí)間: 2025-3-28 11:51 作者: 撤退 時(shí)間: 2025-3-28 16:19
https://doi.org/10.1007/978-0-387-09659-9worldwide by this disease, and the relapsing-remitting form of MS exhibits a gender disequilibrium of 3:1 for female affliction. There are several lines of evidence that multiple sclerosis is an autoimmune disease, which may be modified by genetic factors (see review in .). Following the initial for作者: 富饒 時(shí)間: 2025-3-28 20:29
Knowledge Management Capability Framework,tracutaneous disease at the time of diagnosis. They can be distinguished into cutaneous T-cell lymphomas (CTCL), cutaneous B-cell lymphomas (CBCL) and the rare precursor dendritic cell neoplasms. The PCL are now classified in the new WHO-EORTC classification (.; Table 14.1).作者: 疾馳 時(shí)間: 2025-3-29 01:59 作者: 善辯 時(shí)間: 2025-3-29 06:22 作者: Crepitus 時(shí)間: 2025-3-29 07:45
Wolf-Henning Boehncke,Heinfried H. RadekeFirst comprehensive book on the new drug generation of biologicals.Contains all biologicals presently approved for clinical application.Covers all aspects from the biotechnological production processe作者: Duodenitis 時(shí)間: 2025-3-29 12:36 作者: 貧窮地活 時(shí)間: 2025-3-29 16:01
rs all aspects from the biotechnological production processeThe idea for this book was born during the symposium on biologics organized by ZAFES (Center for Drug Research, Development and Safety at the University of Frankfurt am Main) in September 2005. Highly distinguished researchers special- ing 作者: 匯總 時(shí)間: 2025-3-29 22:16 作者: 幸福愉悅感 時(shí)間: 2025-3-30 00:36
Peter Heisig,Christian Berg,Peter Drtinacess of immune surveillance and mounting an immune response (.): (1) firm adherence to the wall of blood vessels under blood flow, (2) scanning by T cells of other cells within tissues, and (3) formation of the immunological synapse between T cells and antigen-presenting cells (APCs).作者: miracle 時(shí)間: 2025-3-30 07:40 作者: COST 時(shí)間: 2025-3-30 12:10
Adalimumabmay elicit immune responses that potentially limit its long-term use in patients with chronic conditions such as rheumatoid arthritis, adalimumab is fully human, lowering the potential for immunogenicity (.).作者: 咯咯笑 時(shí)間: 2025-3-30 13:24
